Literature DB >> 29618626

Demoralization in Parkinson disease.

Brian B Koo1, Christopher A Chow2, Divya R Shah2, Farhan H Khan2, Brittani Steinberg2, Danielle Derlein2, Keerthana Nalamada2, Kiran Sai Para2, Vikramjeet M Kakade2, Amar S Patel2, John M de Figueiredo2, Elan D Louis2.   

Abstract

OBJECTIVE: To determine the prevalence and associated features of demoralization in Parkinson disease (PD).
METHODS: Participants with PD and controls were prospectively recruited from outpatient movement disorder clinics and the community. Demoralization was defined as scoring positively on the Diagnostic Criteria for Psychosomatic Research, Demoralization questionnaire or Kissane Demoralization Scale score ≥24. Depression was defined as Patient Health Questionnaire-9 score ≥10. Forward stepwise logistic regression was used to determine the odds of having demoralization in the overall, control, and PD cohorts.
RESULTS: Demoralization occurred in 18.1% of 94 participants with PD and 8.1% of 86 control participants (p = 0.05). These 2 groups were otherwise comparable in age, sex, education, economics, race, and marital status. Although demoralization was highly associated with depression, there were individuals with one and not the other. Among participants with PD, 7 of 19 (36.8%) depressed individuals were not demoralized, and 5 of 17 (29.4%) demoralized individuals were not depressed. In the overall cohort, having PD (odds ratio 2.60, 95% confidence interval 1.00-6.80, p = 0.051) was associated with demoralization, along with younger age and not currently being married. In the PD cohort, younger age and Unified Parkinson's Disease Rating Scale, part III score (per score 1) were associated with demoralization (odds ratio 1.06, 95% confidence interval 1.01-1.12, p = 0.02).
CONCLUSIONS: Demoralization is common in PD and is associated with motor dysfunction. In demoralization, there is a prominent inability to cope, making it somewhat distinct from depression. Treatment approaches are also different, making it important to identify demoralization in patients with PD.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29618626      PMCID: PMC5931805          DOI: 10.1212/WNL.0000000000005425

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Assessing demoralization and depression in the setting of medical disease.

Authors:  Lara Mangelli; Giovanni A Fava; Silvana Grandi; Luigi Grassi; Fedra Ottolini; Piero Porcelli; Chiara Rafanelli; Marco Rigatelli; Nicoletta Sonino
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

2.  Use of the Diagnostic Criteria for Psychosomatic Research (DCPR) in a community sample.

Authors:  Lara Mangelli; Federica Semprini; Laura Sirri; Giovanni A Fava; Nicoletta Sonino
Journal:  Psychosomatics       Date:  2006 Mar-Apr       Impact factor: 2.386

Review 3.  Demoralization: a systematic review on its clinical characterization.

Authors:  L Tecuta; E Tomba; S Grandi; G A Fava
Journal:  Psychol Med       Date:  2014-07-17       Impact factor: 7.723

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Diagnostic criteria for use in psychosomatic research.

Authors:  G A Fava; H J Freyberger; P Bech; G Christodoulou; T Sensky; T Theorell; T N Wise
Journal:  Psychother Psychosom       Date:  1995       Impact factor: 17.659

6.  Subjective incompetence, the clinical hallmark of demoralization.

Authors:  J M de Figueiredo; J D Frank
Journal:  Compr Psychiatry       Date:  1982 Jul-Aug       Impact factor: 3.735

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  The Demoralization Scale: a report of its development and preliminary validation.

Authors:  David W Kissane; Simon Wein; Anthony Love; Xiu Qing Lee; Pei Lee Kee; David M Clarke
Journal:  J Palliat Care       Date:  2004       Impact factor: 2.250

9.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Authors:  Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

  9 in total
  5 in total

Review 1.  Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.

Authors:  Maya Katz
Journal:  Neurotherapeutics       Date:  2021-01-13       Impact factor: 7.620

2.  Aggression Towards Caregivers in Parkinson's Disease and Related Disorders: A Mixed Methods Study.

Authors:  Zachary A Macchi; Sandhya Seshadri; Roman Ayele; Meredith Bock; Judith Long; Heather Coats; Janis Miyasaki; Steven Z Pantilat; Maya Katz; Elizabeth J Santos; Stefan H Sillau; Hillary D Lum; Benzi M Kluger
Journal:  Mov Disord Clin Pract       Date:  2022-09-07

3.  From Perceived Stress to Demoralization in Parkinson Disease: A Path Analysis.

Authors:  John M de Figueiredo; Boheng Zhu; Amar Patel; Robert Kohn; Brian B Koo; Elan D Louis
Journal:  Front Psychiatry       Date:  2022-05-10       Impact factor: 5.435

4.  Health-Related Quality of Life Subdomains in Patients with Parkinson's Disease: The Role of Gender.

Authors:  Anja Ophey; Carsten Eggers; Richard Dano; Lars Timmermann; Elke Kalbe
Journal:  Parkinsons Dis       Date:  2018-08-01

Review 5.  Palliative Care in Movement Disorders: an Evolving Field.

Authors:  Zachary A Macchi; Christopher G Tarolli; Benzi M Kluger
Journal:  Curr Neurol Neurosci Rep       Date:  2021-01-28       Impact factor: 5.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.